Drug Profile
AM 543
Latest Information Update: 27 Apr 2000
Price :
$50
*
At a glance
- Originator Zenyth Therapeutics
- Class
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 27 Apr 2000 Discontinued-Preclinical for Pain in Australia (Unknown route)
- 14 Feb 2000 Preclinical development for Pain in Australia (Unknown route)